Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-03-04
DOI
https://doi.org/10.3389/fonc.2026.1814738
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression

Yuanyuan Weng, Fangfang Chen, Yi Shi, Gang Chen
Frontiers in Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression

Yuanyuan Weng, Fangfang Chen, Yi Shi, Gang Chen
article en

Abstract

No abstract available for this paper.
Frontiers in OncologyVol. 16
Fujian Medical University (CN), Fujian Provincial Cancer Hospital (CN)
Good health and well-being
Openalex Percentile: Top 37%
Hepatocellular Carcinoma Treatment and Prognosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.